Page last updated: 2024-12-07
cyclotriphosphazene ester
Description
Cyclotriphosphazene esters are a class of organophosphorus compounds derived from hexachlorocyclotriphosphazene (N3P3Cl6). They are synthesized through a multi-step process involving the reaction of hexachlorocyclotriphosphazene with alcohols or phenols in the presence of a base. These reactions replace the chlorine atoms with alkoxy or aryloxy groups, resulting in the formation of cyclotriphosphazene esters. Cyclotriphosphazene esters have garnered significant attention in various research fields due to their unique properties and potential applications. For instance, they exhibit high thermal stability, flame retardancy, and good dielectric properties. The presence of the phosphazene ring and the tunable nature of the alkoxy or aryloxy substituents allow for the fine-tuning of their physical and chemical properties. Cyclotriphosphazene esters have been investigated as flame retardants for polymers, additives for lubricants, and materials for optical and electronic applications. Research efforts are focused on understanding the structure-property relationships, exploring novel synthetic methodologies, and developing new applications for these versatile compounds.'
cyclotriphosphazene ester: hydraulic fluid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1,3,5,2,4,6-triazatriphosphinine : An inorganic heteromonocyclic compound that is 1,3,5-triazine in which the carbon atoms have been replaced by phosphorus atoms. It was one of a series of compounds which was being developed for use as a fire-resistant hydraulic fluid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (10)
Synonym |
1,3,5,2,4,6-triazatriphosphinine |
CHEBI:167642 |
2,4,6-triphospha-1,3,5-triazine |
291-37-2 |
phosphonitrile trimer |
cyclotriphosphazene ester |
cyclotriphosphazene |
1,3,5,2,4,6-triazatriphosphorine |
cyclotriphosphazatriene |
DTXSID90183351 |
Research Excerpts
Toxicity
Compound-Compound Interactions
Excerpt | Reference | Relevance |
"Derivatives of the tri-spirane pentaerythritoxy-cyclophosphazene compound, 1, have been used to investigate the stereogenic properties of spiranes combined with four equivalent conventional centres of chirality." | ( Stereogenic properties of spiranes combined with four equivalent conventional centres of chirality. Coles, SJ; Davies, DB; Eaton, RJ; Hursthouse, MB; KiliƧ, A; Shaw, RA; Uslu, A, 2007) | 0.34 |
Drug Classes (4)
Class | Description |
nitrogen molecular entity | |
phosphorus molecular entity | |
inorganic heteromonocyclic compound | |
inorganic aromatic compound | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 8 (61.54) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.04 (24.57) | Research Supply Index | 2.77 (2.92) | Research Growth Index | 4.81 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |